Sonoma Pharmaceuticals Enters Material Definitive Agreement

TL;DR

Sonoma Pharma just signed a big deal, filing an 8-K on Jan 29, 2025.

AI Summary

Sonoma Pharmaceuticals, Inc. announced on January 29, 2025, that it entered into a Material Definitive Agreement. The company, formerly known as Oculus Innovative Sciences, Inc., is incorporated in Delaware and headquartered in Boulder, Colorado.

Why It Matters

This filing indicates a significant business transaction for Sonoma Pharmaceuticals, Inc., which could impact its future operations and financial performance.

Risk Assessment

Risk Level: medium — Entering into a material definitive agreement can introduce new risks related to the terms of the agreement, counterparty performance, and integration challenges.

Key Players & Entities

• Sonoma Pharmaceuticals, Inc. (company) — Registrant
• January 29, 2025 (date) — Date of earliest event reported
• Oculus Innovative Sciences, Inc. (company) — Former company name
• Delaware (jurisdiction) — State of incorporation
• Boulder, CO (location) — Address of principal executive offices

FAQ

Filing Documents

• sonoma_8k.htm (8-K) — 30KB
• sonoma_ex1001.htm (EX-10.1) — 108KB
• 0001683168-25-000611.txt ( ) — 335KB
• snoa-20250129.xsd (EX-101.SCH) — 3KB
• snoa-20250129_lab.xml (EX-101.LAB) — 33KB
• snoa-20250129_pre.xml (EX-101.PRE) — 24KB
• sonoma_8k_htm.xml (XML) — 4KB

01 Entry into a Material Definitive Agreement

Item 1.01 Entry into a Material Definitive Agreement. Effective January 29, 2025, we entered into a Master Supply Agreement with WellSpring Pharmaceutical Corporation for the sale of Microcyn technology-based products to large retailers in the United States. The agreement is for an initial term of two years, subject to three automatic one-year renewal periods. The foregoing description of the agreement is not complete and is qualified in its entirety by reference to the full text of the agreement, a copy of which is filed herewith as Exhibit 10.1. This report contains forward-looking strategies, predictions or any other statements related to our future activities, or future events or conditions. These statements are based on current expectations, estimates and projections about our business based, in part, on assumptions made by management. These Therefore, actual outcomes and results may differ materially from what is expressed or forecasted in the forward-looking statements due to numerous factors, including those risks discussed in our Annual Report on Form 10-K and in other documents that we file from time to time with the SEC. Any forward-looking statements speak only as of the date on which they are made, and we do not undertake any obligation to update any forward-looking statement to reflect events or circumstances after the date of this report, except as required by law.

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits . Exhibit Number Description 10.1 * Master Supply Agreement, dated January 29, 2025, by and between Sonoma Pharmaceuticals, Inc. and WellSpring Pharmaceutical Corporation. 104 Cover Page Interactive Data File (formatted in Inline XBRL in Exhibit 101). ___________________ Certain portions of the agreement have been omitted to preserve the confidentiality of such information. The Company will furnish copies of any such information to the SEC upon request. * Some exhibits or schedules to the agreement have been omitted from this filing pursuant to Item 601(a)(5) of Regulation S-K. The Company will furnish copies of any such schedule or exhibit to the SEC upon request. 2

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SONOMA PHARMACEUTICALS, INC. Date: January 30, 2025 By: /s/ Amy Trombly Name: Title: Amy Trombly Chief Executive Officer 3

View Full Filing

View this 8-K filing on SEC EDGAR